News | September 10, 2024
Aptar Pharma and Pulmotree to develop and promote Kolibri non-propellant liquid inhaler platform
Agreement further expands Aptar Pharma’s leading respiratory portfolio
Agreement further expands Aptar Pharma’s leading respiratory portfolio
The company will address these observations within the stipulated timeline
Utidelone can penetrate BBB due to its unique physicochemical characteristics and insusceptibility to P-glycoprotein-mediated efflux
The initiative aims to empower individuals to take proactive steps towards monitoring their health
Shelter Pharma Limited secured an order from Berlin International Medical Co D3Cure 50 ml x 30000 pcs
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
New facility is part of Aptar Pharma’s global expansion program
GMM Pfaudler US completes acquisition of MixPro
Collaboration enables Brenntag to serve pharma customers in EMEA with chromatography silica gels
Subscribe To Our Newsletter & Stay Updated
